secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001739410-24-000114
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q2 net loss $16.2M; cash $88.6M; RLYB212 Phase 2 on track for Q4 2024
------------------------------------------------------------------------------

- Q2 net loss $16.2M ($0.37/share) vs $18.6M ($0.46/share) in Q2 2023.
- Revenue $0.3M from J&J collaboration; no revenue in prior year.
- Cash, equivalents, and securities $88.6M as of June 30, expecting runway into mid-2026.
- RLYB212 Phase 2 trial in pregnant women at risk of FNAIT remains on track to start Q4 2024.
- Epidemiological analysis estimates >30,000 higher-risk pregnancies/year in North America and major European countries, 40% above prior estimates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000114/0001739410-24-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000114/rlyb-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001739410-24-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer